Pml represses tumour progression through inhibition of mTOR

EMBO Molecular Medicine

Volumn 3, Issue 5, 2011, Pages 249-257

  Bernardi, Rosa ^a,b   Papa, Antonella ^a   Egia, Ainara ^a   Coltella, Nadia ^a,b   Teruya Feldstein, Julie ^c   Signoretti, Sabina ^d   Pandolfi, Pier Paolo ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cyst; Kidney; MTOR; PML; Tumour

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROMYELOCYTIC LEUKEMIA PROTEIN; TUBERIN;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; ENZYME INDUCTION; GENE INACTIVATION; HETEROZYGOSITY LOSS; HYPOXIA; KIDNEY CARCINOMA; KIDNEY CYST; KIDNEY INJURY; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOMA; CROSSES, GENETIC; GENE EXPRESSION REGULATION; HISTOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; MICE; MICE, KNOCKOUT; NUCLEAR PROTEINS; RADIOGRAPHY, ABDOMINAL; REPRESSOR PROTEINS; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 79955642358     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201100130     Document Type: Article

References (22)

1. Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J, Cordon-Cardo C, Simon MC, Rafii S, Pandolfi PP (2006) PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 442: 779- 785
2. Bhaskar PT, Hay N (2007) The two TORCs and Akt. Dev Cell 12: 487- 502
3. Bonnet CS, Aldred M, von Ruhland C, Harris R, Sandford R, Cheadle JP (2009) Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis. Hum Mol Genet 18: 2166- 2176
4. de Peralta-Venturina M, Moch H, Amin M, Tamboli P, Hailemariam S, Mihatsch M, Javidan J, Stricker H, Ro JY, Amin MB (2001) Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 25: 275- 284
5. Green AJ, Johnson PH, Yates JR (1994) The tuberous sclerosis gene on chromosome 9q34 acts as a growth suppressor. Hum Mol Genet 3: 1833- 1834
6. Harrington LS, Findlay GM, Lamb RF (2005) Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci 30: 35- 42
7. Henske EP, Scheithauer BW, Short MP, Wollmann R, Nahmias J, Hornigold N, van Slegtenhorst M, Welsh CT, Kwiatkowski DJ (1996) Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions. Am J Hum Genet 59: 400- 406
8. Huang J, Manning BD (2009) A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 37: 217- 222
9. Huang J, Wu S, Wu CL, Manning BD (2009) Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res 69: 6107- 6114
10. Kenerson H, Dundon TA, Yeung RS (2005) Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res 57: 67- 75
11. Kobayashi T, Minowa O, Kuno J, Mitani H, Hino O, Noda T (1999) Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. Cancer Res 59: 1206- 1211
12. Lacher MD, Pincheira R, Zhu Z, Camoretti-Mercado B, Matli M, Warren RS, Castro AF (2010) Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis. Oncogene 29: 6543- 6556
13. Ma L, Teruya-Feldstein J, Behrendt N, Chen Z, Noda T, Hino O, Cordon-Cardo C, Pandolfi PP (2005) Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev 19: 1779- 1786
14. Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC (2005) Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev 19: 1773- 1778
15. +/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest 104: 687- 695
16. Pollizzi K, Malinowska-Kolodziej I, Stumm M, Lane H, Kwiatkowski D (2009) Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis. Mol Cancer 8: 38
17. Sampson JR (2009) Therapeutic targeting of mTOR in tuberous sclerosis. Biochem Soc Trans 37: 259- 264
18. Shiono M, Kobayashi T, Takahashi R, Sun G, Abe M, Zhang D, Wang L, Piao X, Takagi Y, Mineki R, et al (2008) The G1556S-type tuberin variant suppresses tumor formation in tuberous sclerosis 2 mutant (Eker) rats despite its deficiency in mTOR inhibition. Oncogene 27: 6690- 6697
19. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP (2006) Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441: 523- 527
20. Wilson C, Idziaszczyk S, Parry L, Guy C, Griffiths DF, Lazda E, Bayne RA, Smith AJ, Sampson JR, Cheadle JP (2005) A mouse model of tuberous sclerosis 1 showing background specific early post-natal mortality and metastatic renal cell carcinoma. Hum Mol Genet 14: 1839- 1850
21. +/- mice. Cancer Res 66: 7934- 7938
22. Zhou J, Brugarolas J, Parada LF (2009) Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1. Hum Mol Genet 18: 4428- 4441